Phospho-specific flow cytometry for pharmacodynamic monitoring of immunosuppressive therapy in transplantation

Transplantation Research

Volumn 1, Issue 1, 2012, Pages

  Baan, Carla ^a   Bouvy, Anne ^a   Vafadari, Ramin ^a   Weimar, Willem ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Immunosuppressive medication; Kidney transplantation; Phospho specific flow cytometry; Regulatory T cells

Indexed keywords

ALEFACEPT; ALEMTUZUMAB; B7 ANTIGEN; BELATACEPT; BORTEZOMIB; CALCINEURIN INHIBITOR; CD3 ANTIGEN; CD40 ANTIGEN; CD45 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EFALIZUMAB; EVEROLIMUS; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; PROTEIN TYROSINE PHOSPHATASE; RAPAMYCIN; RITUXIMAB; SOTRASTAURIN; STAT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STEROID; STRESS ACTIVATED PROTEIN KINASE; TOFACITINIB; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; CELL FUNCTION; CHRONIC GRAFT REJECTION; CLINICAL PRACTICE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SENSITIVITY; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNE RESPONSE; IMMUNOREACTIVITY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 84911098464     PISSN: None     EISSN: 20471440     Source Type: Journal    
DOI: 10.1186/2047-1440-1-20     Document Type: Review

References (34)

1. Cantrell DA. T-cell antigen receptor signal transduction. Immunology 2002, 105:369-374. 10.1046/j.1365-2567.2002.01391.x, 1782684, 11985657.
2. Adams JJ, Narayanan S, Liu B, Birnbaum ME, Kruse AC, Bowerman NA, Chen W, Levin AM, Connolly JM, Zhu C, Kranz DM, Garcia KC. T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex. Immunity 2011, 35:681-693. 10.1016/j.immuni.2011.09.013, 3253265, 22101157.
3. Aivazian D, Stern LJ. Phosphorylation of T cell receptor zeta is regulated by a lipid dependent folding transition. Nat Struct Biol 2000, 7:1023-1026. 10.1038/80930, 11062556.
4. Sun Z, Arendt CW, Ellmeier W, Schaeffer EM, Sunshine MJ, Gandhi L, Annes J, Petrzilka D, Kupfer A, Schwartzberg PL, Littman DR. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 2000, 404:402-407. 10.1038/35006090, 10746729.
5. Budde K, Sommerer C, Becker T, Asderakis A, Pietruck F, Grinyo JM, Rigotti P, Dantal J, Ng J, Barten MJ, Weber M. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. Am J Transplant 2010, 10:571-581. 10.1111/j.1600-6143.2009.02980.x, 20121745.
6. Friman S, Arns W, Nashan B, Vincenti F, Banas B, Budde K, Cibrik D, Chan L, Klempnauer J, Mulgaonkar S, Nicholson M, Wahlberg J, Wissing KM, Abrams K, Witte S, Woodle ES. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant 2011, 11(7):1444-1455. 10.1111/j.1600-6143.2011.03538.x, 21564523.
7. Kane LP, Lin J, Weiss A. It's all Rel-active: NF-κB and CD28 costimulation of T cell activation. Trends Immunol 2002, 23:413-420. 10.1016/S1471-4906(02)02264-0, 12133805.
8. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010, 10:535-546. 10.1111/j.1600-6143.2009.03005.x, 20415897.
9. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, Rial Mdel C, Florman S, Block A, Di Russo G, Xing J, Garg P, Grinyó J. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010, 10:547-557. 10.1111/j.1600-6143.2010.03016.x, 20415898.
10. Vincenti F, Larsen CP, Alberuc J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G, Reyes-Acevedo R, Rice K, Rostaing L, Steinberg S, Xing J, Agarwal M, Harler MB, Charpentier B. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012, 12(1):210-217. 10.1111/j.1600-6143.2011.03785.x, 21992533.
11. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009, 9:480-490. 10.1038/nri2580, 2814538, 19543225.
12. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007, 178:2623-2629.
13. Busque S, Leventhal J, Brennan DC, Steinberg S, Klintmalm G, Shah T, Mulgaonkar S, Bromberg JS, Vincenti F, Hariharan S, Slakey D, Peddi VR, Fisher RA, Lawendy N, Wang C, Chan G. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant 2009, 9:1936-1945. 10.1111/j.1600-6143.2009.02720.x, 19660021.
14. Vincenti F, Tedesco Silva H, Busque S, O'Connell P, Friedewald J, Cibrik D, Budde K, Yoshida A, Cohney S, Weimar W, Kim YS, Lawendy N, Shirley Lan SP, Kudlacz E, Krishnaswami S, Chan G. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant 2012, Epub ahead of print.
15. Calarota SA, Zelini P, De Silvestri A, Chiesa A, Comolli G, Sarchi E, Migotto C, Pellegrini C, Esposito P, Minoli L, Tinelli C, Marone P, Baldanti F. Kinetics of T-lymphocyte subsets and posttransplant opportunistic infections in heart and kidney transplant recipients. Transplantation 2012, 93:112-119. 10.1097/TP.0b013e318239e90c, 22134368.
16. Thibaudin D, Alamartine E, Mariat C, Absi L, Berthoux F. Long-term kinetic of T-lymphocyte subsets in kidney-transplant recipients: Influence of anti-T-cell antibodies and association with posttransplant malignancies. Transplantation 2005, 80:1514-1517. 10.1097/01.tp.0000181193.98026.3f, 16340799.
17. Trzonkowski P, Zilvetti M, Friend P, Wood KJ. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1 H induction with reduced maintenance immunosuppression. Transplantation 2006, 82:1342-1351. 10.1097/01.tp.0000239268.64408.84, 17130784.
18. Kho MM, Bouvy AP, Cadogan M, Kraaijeveld R, Baan CC, Weimar W. The effect of low and ultra-low dosages Thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients. Transpl Immunol 2012, 26:186-190. 10.1016/j.trim.2012.02.003, 22410573.
19. Sewgobind VD, Kho MM, van der Laan LJ, Hendrikx TK, van Dam T, Tilanus HW, IJzermans JN, Weimar W, Baan CC. The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients. Nephrol Dial Transplant 2009, 24:1635-1644. 10.1093/ndt/gfn778, 19176684.
20. Louis S, Braudeau C, Giral M, Dupont A, Moizant F, Robillard N, Moreau A, Soulillou JP, Brouard S. Contrasting CD25hiCD4 + T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006, 81:398-407. 10.1097/01.tp.0000203166.44968.86, 16477227.
21. Gurkan S, Luan Y, Dhillon N, Allam SR, Montague T, Bromberg JS, Ames S, Lerner S, Ebcioglu Z, Nair V, Dinavahi R, Sehgal V, Heeger P, Schroppel B, Murphy B. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010, 10:2132-2141. 10.1111/j.1600-6143.2010.03210.x, 20883548.
22. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4 + CD25 + FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006, 177:8338-8347.
23. Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4 + CD25 + Foxp3+ regulatory T cells. Blood 2011, 118:2342-2350. 10.1182/blood-2010-10-313684, 21734238.
24. Hendrikx TK, Velthuis JH, Klepper M, van Gurp E, Geel A, Schoordijk W, Baan CC, Weimar W. Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients. Transpl Int 2009, 22:884-891. 10.1111/j.1432-2277.2009.00890.x, 19453998.
25. Hendrikx TK, van Gurp EA, Sewgobind VD, Mol WM, Schoordijk W, Klepper M, Velthuis JH, Geel A, Ijzermans JN, Weimar W, Baan CC. Generation of donor-specific regulatory T-cell function in kidney transplant patients. Transplantation 2009, 87:376-383. 10.1097/TP.0b013e3181901b69, 19202442.
26. van Gurp EA, Schoordijk-Verschoor W, Klepper M, Korevaar SS, Chan G, Weimar W, Baan CC. The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. Transplantation 2009, 87:79-86. 10.1097/TP.0b013e31818bbea7, 19136895.
27. Dieterlen MT, Bittner HB, Klein S, von Salisch S, Mittag A, Tárnok A, Dhein S, Mohr FW, Barten MJ. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood. Cytometry B Clin Cytom 2012, 82:151-157.
28. Wu S, Jin L, Vence L, Radvanyi LG. Development and application of 'phosphoflow' as a tool for immunomonitoring. Expert Rev Vaccines 2010, 9:631-643. 10.1586/erv.10.59, 2933839, 20518718.
29. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007, 4(5):e176. 10.1371/journal.pmed.0040176, 1865558, 17488182.
30. Huang X, Guo Y, Bao C, Shen N. Multidimensional single cell based STAT phosphorylation profiling identifies a novel biosignature for evaluation of systemic lupus erythematosus activity. PLoS One 2011, 6(7):e21671. 10.1371/journal.pone.0021671, 3142107, 21799742.
31. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Poa C, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003, 302:875-878. 10.1126/science.1087061, 14593182.
32. Vafadari R, Hesselink DA, Cadogan M, Weimar W, Baan CC. The inhibitory effect of tacrolimus on p38 MAPK signaling in kidney transplant recipients measured by whole blood phosphospecific flow cytometry. Transplantation 2012, Epub ahead of print.
33. Lyons GE, Roszkowski JJ, Man S, Yee C, Kast WM, Nishimura MI. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother 2006, 55(9):1142-1150. 10.1007/s00262-005-0103-9, 16374636.
34. Herzenberg LA, Tung J, Moore WA, Herzenberg LA, Parks DR. Interpreting flow cytometry data: a guide for the perplexed. Nat Immunol 2006, 7(7):681-685. 10.1038/ni0706-681, 16785881.